BWM
GALT icon

BT Wealth Management’s Galectin Therapeutics GALT Stock Holding History

BT Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-60,000
Closed -$118K – 59
2020
Q1 		$118K Buy
60,000
+2,991
+5% +$7.28K 0.07% 52
2019
Q4 		$163K Hold
57,009
– – 0.08% 63
2019
Q3 		$209K Hold
57,009
– – 0.12% 51
2019
Q2 		$189K Buy
57,009
+7,009
+14% +$30.4K 0.11% 52
2019
Q1 		$256K Hold
50,000
– – 0.15% 46
2018
Q4 		$249K Buy
+50,000
New +$239K 0.11% 85

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BT Wealth Management's GALT Position: Q2 2020 in Review

BT Wealth Management sold out of Galectin Therapeutics (GALT) in Q2 2020, closing a stake of 60,000 shares — an estimated $118K sold.

BT Wealth Management first reported a position in GALT in Q4 2018 and held it in 6 quarters. The position peaked at $256K in Q1 2019. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2020.

  • BT Wealth Management reported no remaining Galectin Therapeutics position as of Q2 2020 after selling out during the quarter.
  • BT Wealth Management sold 60,000 Galectin Therapeutics shares in Q2 2020, an estimated $118K.
  • BT Wealth Management first reported a position in Galectin Therapeutics in Q4 2018 and held it in 6 quarters.
  • BT Wealth Management's Galectin Therapeutics position peaked at $256K in Q1 2019.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2020.

Based on BT Wealth Management's 13F filing for Q2 2020, filed 21 Jul 2020.